** Shares of drug developer Hoth Therapeutics HOTH.O jump 96.4% to $1.61 premarket
** Co announces positive interim safety and efficacy results from a mid-stage trial testing its experimental treatment to treat skin toxicity caused due to side effects of cancer treatments
** Co was testing the treatment, HT-001, to address skin toxicities linked to a type of cancer medication called EGFR inhibitors
** Data from the study shows that 100% of patients enrolled in the trial had significant skin toxicity improvement by six weeks
** 66% of patients reported reduced pain and itching scores - HOTH
** Co says no treatment-related adverse effects have been reported
** Up to last close, stock had fallen ~47% in the past 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。